medscopeglobal.com · EMA · EPAR

EPAR a stanoviska

Evropské veřejné hodnotící zprávy (EPAR) a stanoviska CHMP.

Kaftrio, ivacaftor, tezacaftor, elexacaftor

EMA · Kaftrio · 31. 7. 2026

European public assessment report (EPAR) for Kaftrio, a medicine containing the active substances ivacaftor, tezacaftor and elexacaftor. It is used to treat cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in their CFTR gene.

Kaftrio, ivacaftor, tezacaftor, elexacaftor

Multaq (dronedarone) - European Public Assessment Report

Aspaveli (pegcetacoplan) authorised by EMA

Iclusig (ponatinib) - European Medicines Agency

Qoyvolma (ustekinumab) - EMA

Xofigo (radium Ra223 dichloride)

Gilenya (fingolimod) - European public assessment report

Sylvant (siltuximab) authorised by EMA

Boey (trenibotulinumtoxinE) Authorised by EMA

Jascayd (nerandomilast) authorised by EMA

Mayzent (siponimod) authorised in the EU

Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 35, Status: Withdrawn

Human medicines European public assessment report (EPAR): Cerdelga, eliglustat, Date of authorisation: 19/01/2015, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Macitentan Accord, macitentan, Date of authorisation: 24/09/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Macitentan AccordPharma, macitentan, Date of authorisation: 24/09/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Apixaban Accord, apixaban, Date of authorisation: 23/07/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Irbesartan Zentiva (previously Irbesartan Winthrop), irbesartan, Date of authorisation: 19/01/2007, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Cavoley, pegfilgrastim, Status: Opinion

Human medicines European public assessment report (EPAR): Qezzaqar, catequentinib

Human medicines European public assessment report (EPAR): Susvimo, ranibizumab, Status: Opinion

Human medicines European public assessment report (EPAR): Ubeslo, obicetrapib, Status: Opinion

Human medicines European public assessment report (EPAR): Azacitidine Adienne, azacitidine, Status: Application withdrawn

Human medicines European public assessment report (EPAR): Lynavoy, Linerixibat, Status: Opinion

European public assessment report (EPAR): Zokovea, ensitrelvir

Human medicines European public assessment report (EPAR): Lyrokaul, lerodalcibep, Status: Opinion

Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 62, Status: Authorised

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 61, Status: Authorised

Human medicines European public assessment report (EPAR): Meplyffa, arimoclomol, Status: Opinion

Human medicines European public assessment report (EPAR): Nezglyal, leriglitazone, Status: Opinion

Summary of opinion: Trodelvy, 23/07/2026 Positive

European Medicines Agency (EMA) Authorises Ryjunea (atropine sulfate)

Lumykras : EPAR - Risk management plan

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 8, Status: Authorised

Opdualag, relatlimab, nivolumab

Human medicines European public assessment report (EPAR): Flucelvax, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 15/11/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Inaqovi, cedazuridine,decitabine, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Zemcelpro, allogeneic umbilical cord-derived CD34- cells, non-expanded,dorocubicel, Date of authorisation: 25/08/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Xervyteg, Allogeneic faecal microbiota, pooled, Status: Opinion

Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Date of authorisation: 18/11/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Vaxneuvance, pneumococcal polysaccharide conjugate vaccine (adsorbed), Date of authorisation: 13/12/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Maviret, glecaprevir,pibrentasvir, Date of authorisation: 26/07/2017, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Date of authorisation: 29/06/2004, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Yartemlea, Narsoplimab, Status: Opinion under re-examination

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Paxneury, guanfacine, Date of authorisation: 26/02/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Qaialdo, spironolactone, Date of authorisation: 26/05/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Bildyos, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Ekterly, sebetralstat, Date of authorisation: 17/09/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Tuznue, trastuzumab, Date of authorisation: 19/09/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Hemgenix, etranacogene dezaparvovec, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Poulvac Procerta HVT-ND, Marek’s disease and Newcastle disease vaccine (live recombinant), Status: Authorised

Human medicines European public assessment report (EPAR): Abasaglar (previously Abasria), insulin glargine, Date of authorisation: 09/09/2014, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Humalog, insulin lispro, Date of authorisation: 30/04/1996, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Kostaive, zapomeran, Date of authorisation: 12/02/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Fendrix, hepatitis B (rDNA) vaccine (adjuvanted, adsorbed), Date of authorisation: 02/02/2005, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 18, Status: Withdrawn

Human medicines European public assessment report (EPAR): Venclyxto, venetoclax, Date of authorisation: 04/12/2016, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Vaxchora, cholera vaccine, oral, live, Date of authorisation: 01/04/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Neofordex, dexamethasone, Date of authorisation: 16/03/2016, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Esbriet, pirfenidone, Date of authorisation: 28/02/2011, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Ztalmy, ganaxolone, Date of authorisation: 26/07/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Evenity, romosozumab, Date of authorisation: 09/12/2019, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Ryzneuta, efbemalenograstim alfa, Date of authorisation: 21/03/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Cervarix, human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed), Date of authorisation: 20/09/2007, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Adynovi, rurioctocog alfa pegol, Date of authorisation: 08/01/2018, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Zavesca, miglustat, Date of authorisation: 20/11/2002, Date of refusal: 16/06/2009, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Tolura, telmisartan, Date of authorisation: 04/06/2010, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Ebixa, memantine, Date of authorisation: 15/05/2002, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Trazimera, trastuzumab, Date of authorisation: 26/07/2018, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Wyost, denosumab, Date of authorisation: 17/05/2024, Revision: 4, Status: Authorised